Horizon Pharma (HZNP) and Galena Biopharma (GALE) Financial Contrast

Horizon Pharma (NASDAQ: HZNP) and Galena Biopharma (NASDAQ:GALE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Horizon Pharma and Galena Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Pharma -45.28% 20.22% 5.35%
Galena Biopharma N/A -92.98% -33.83%

Valuation & Earnings

This table compares Horizon Pharma and Galena Biopharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Horizon Pharma $981.12 million 2.59 -$166.83 million ($3.04) -5.11
Galena Biopharma N/A N/A -$23.54 million ($18.16) -0.01

Galena Biopharma has lower revenue, but higher earnings than Horizon Pharma. Horizon Pharma is trading at a lower price-to-earnings ratio than Galena Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.6% of Horizon Pharma shares are owned by institutional investors. Comparatively, 16.6% of Galena Biopharma shares are owned by institutional investors. 3.2% of Horizon Pharma shares are owned by company insiders. Comparatively, 0.8% of Galena Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Horizon Pharma has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Galena Biopharma has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Pharma and Galena Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Pharma 0 2 9 0 2.82
Galena Biopharma 0 3 0 0 2.00

Horizon Pharma presently has a consensus target price of $18.64, indicating a potential upside of 20.00%. Galena Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,438.46%. Given Galena Biopharma’s higher probable upside, analysts plainly believe Galena Biopharma is more favorable than Horizon Pharma.

Summary

Horizon Pharma beats Galena Biopharma on 8 of the 13 factors compared between the two stocks.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Galena Biopharma Company Profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.